Theranostics in Oncology-Thriving, Now More than Ever

Area of Science:

• Nuclear medicine and oncology
• Radiopharmaceutical therapy
• Molecular imaging

Background:

• Theranostics in nuclear oncology, originating in the 1940s, leverages image-guided therapy for diverse cancers.
• Theranostic agents offer significant improvements in progression-free and overall survival, with a favorable safety profile.

Discussion:

• This Special Issue features nine articles exploring theranostics for neuroendocrine neoplasms, prostate cancer, meningioma, and neuroblastoma.
• Investigated radiotracers target established (somatostatin receptor, PSMA, NET) and emerging (CXCR4) biomarkers.
• Theranostics are integrated with advanced techniques like radiomics and novel reconstruction algorithms for outcome prediction.

Key Insights:

• Theranostics demonstrate efficacy across multiple cancer types, including rare and aggressive tumors.
• Targeting specific molecular structures enhances treatment precision and patient outcomes.
• Combining theranostics with advanced imaging analysis refines treatment strategies and prognostic capabilities.

Outlook:

• Theranostics continue to evolve, offering a thriving and expanding frontier in cancer care.
• Future research will likely focus on novel targets and advanced integration with AI-driven imaging analysis.
• The enduring clinical relevance of theranostics underscores its critical role in personalized oncology.